Pemetrexed Stada 25 mg/ml infuusiokonsentraatti, liuosta varten Finland - finsk - Fimea (Suomen lääkevirasto)

pemetrexed stada 25 mg/ml infuusiokonsentraatti, liuosta varten

stada arzneimittel ag - pemetrexed disodium hemipentahydrate - infuusiokonsentraatti, liuosta varten - 25 mg/ml - pemetreksedi

Imatinib STADA 600 mg tabletti, kalvopäällysteinen Finland - finsk - Fimea (Suomen lääkevirasto)

imatinib stada 600 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - imatinib mesylate - tabletti, kalvopäällysteinen - 600 mg - imatinibi

Hyftor Den europeiske union - finsk - EMA (European Medicines Agency)

hyftor

plusultra pharma gmbh - sirolimuusin - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.

Cliovelle 1 mg / 0,5 mg tabletti Finland - finsk - Fimea (Suomen lääkevirasto)

cliovelle 1 mg / 0,5 mg tabletti

dr. kade pharmazeutische fabrik gmbh - norethisterone acetate, estradiol valerate - tabletti - 1 mg / 0,5 mg - noretisteroni ja estrogeeni

Nustendi Den europeiske union - finsk - EMA (European Medicines Agency)

nustendi

daiichi sankyo europe gmbh - bempedoic happo, etsetimibi - hypercholesterolemia; dyslipidemias - lipidimodifioivat aineet - nustendi on tarkoitettu aikuisille, joilla on primaarinen hyperkolesterolemia (heterotsygoottinen familiaalinen ja ei-familiaalinen) tai sekamuotoinen dyslipidemia, lisänä ruokavalio:yhdessä statiinin potilaille, kykene saavuttamaan ldl-c tavoitteet suurin siedetty annos statiinia lisäksi ezetimibealone potilailla, jotka ovat joko statiini-intoleranssi tai joille statiini on vasta-aiheinen, ja eivät pääse ldl-c tavoitteita etsetimibi yksin,potilaille, joita jo hoidettiin yhdistelmä bempedoic happo ja etsetimibi erillisinä tabletteina kanssa tai ilman statiinia.

IMATINIB ARISTO 100 mg tabletti, kalvopäällysteinen Finland - finsk - Fimea (Suomen lääkevirasto)

imatinib aristo 100 mg tabletti, kalvopäällysteinen

aristo pharma gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 100 mg - imatinibi

IMATINIB ARISTO 400 mg tabletti, kalvopäällysteinen Finland - finsk - Fimea (Suomen lääkevirasto)

imatinib aristo 400 mg tabletti, kalvopäällysteinen

aristo pharma gmbh - imatinibi mesylas - tabletti, kalvopäällysteinen - 400 mg - imatinibi

EZETIMIB ARISTO 10 mg tabletti Finland - finsk - Fimea (Suomen lääkevirasto)

ezetimib aristo 10 mg tabletti

aristo pharma gmbh - ezetimibum - tabletti - 10 mg - etsetimibi

TIBOLON ARISTO 2.5 mg tabletti Finland - finsk - Fimea (Suomen lääkevirasto)

tibolon aristo 2.5 mg tabletti

aristo pharma gmbh - tibolonum - tabletti - 2.5 mg - tiboloni

Imatinib Koanaa Den europeiske union - finsk - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiset aineet - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. potilaat, joilla on alhainen tai hyvin alhainen riski toistumisen pitäisi saada adjuvanttihoitona. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. paitsi äskettäin diagnosoitu kroonisen vaiheen kml, ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia.